We assessed the role of fibrinogen levels on angiographic progression and long-term survival among 111 patients with coronary disease enrolled in the Armed Forces Regression Study (AFREGS). Baseline fibrinogen levels and quantitative coronary angiography were performed initially and at 30 months. Progression or nonregression of coronary disease was more prevalent in patients with high fibrinogen than patients with normal fibrinogen (66.1% vs 45.5%; P = .022). Twelve-year cardiovascular (CV) mortality was substantially higher if fibrinogen was elevated (17.9% vs 3.6%, P = .016). Among patients with elevated fibrinogen and angiographic progression or nonregression, there were 10 deaths and all were CV. Elevated levels of fibrinogen predict the angiographic progression of existing coronary disease and likelihood of CV death. Among patients with elevated levels of fibrinogen, angiographic progression identifies a significantly increased likelihood of a fatal CV event.
Ross R.Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(24):115-126.
2.
Ballantyne CM , Nambi V.Markers of inflammation and their clinical significance. Atheroscler Suppl. 2005;6(2):21-29.
3.
Danesh J., Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med . 2004;350(14): 1387-1397.
4.
Blankenberg S. , Tiret L., Bickel C., et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation . 2002;106(1):24-30.
5.
Ernst E.Fibrinogen: a ‘‘new’’ cardiovascular risk factor. Wien Med Wochenschr. 1991;141(17):375-382.
6.
de Maat MP, Pietersma A., Kofflard M., Sluiter W., Kluft C.Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis. 1996; 121(2):185-191.
7.
Danesh J., Lewington S., Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis . JAMA. 2005;294(14):1799-1809.
Thompson SG, Kienast J., Pyke SD, Haverkate F., van de Loo JCHemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332(10):635-641.
10.
Espinola-Klein C., Rupprecht HJ, Bickel C., et al. Inflammation, atherosclerotic burden and cardiovascular prognosis. Atherosclerosis. 2007;195(2):e126-e134.
11.
Kakafika AI , Liberopoulos EN, Mikhailidis DPFibrinogen: a predictor of vascular disease . Curr Pharm Des. 2007;13(16): 1647-1659.
12.
Dejana E., Languino LR, Polentarutti N., et al. Interaction between fibrinogen and cultured endothelial cells . Induction of migration and specific binding. J Clin Invest . 1985;75(11):11-18.
13.
Naito M., Hayashi T., Kuzuya M., Funaki C., Asai K., Kuzuya F.Effects of fibrinogen and fibrin on the migration of vascular smooth muscle cells in vitro. Atherosclerosis. 1990;83(1):9-14.
14.
Tracy RP, Arnold AM, Ettinger W., Fried L., Meilahn E., Savage P.The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study . Arterioscler Thromb Vasc Biol. 1999;19(7):1776-1783.
15.
Kannel WB, Wolf PA, Castelli WP, D’Agostino RBFibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA. 1987;258(9):1183-1186.
16.
Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med. 2005;142(2):95-104.
17.
Chitolie A. , Mackie IJ, Grant D., Hamilton JL, Machin SMInaccuracy of the ‘derived’ fibrinogen measurement. Blood Coagul Fibrinolysis. 1994 ;5(6):955-957.
18.
Danesh J., Collins R., Appleby P., Peto R.Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279(18):1477-1482.
19.
Green D., Foiles N., Chan C., Schreiner PJ, Liu K.Elevated fibrinogen levels and subsequent subclinical atherosclerosis: the CAR-DIA Study. Atherosclerosis.2009;202(2):623-631.
20.
Bolibar I., Kienast J., Thompson SG, Matthias R., Niessner H., Fechtrup C.Relation of fibrinogen to presence and severity of coronary artery disease is independent of other coexisting heart disease. The ECAT Angina Pectoris Study Group. Am Heart J. 1993;125(6):1601-1605.
21.
Hartmann M. , von Birgelen C., Mintz GS, et al. Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries. J Am Coll Car-diol. 2006;48(3):446-452.
22.
Ernst E., Koenig W.Fibrinogen and cardiovascular risk. Vasc Med. 1997;2(2):115-25.
23.
Kockx M., de Maat MP, Knipscheer HC, et al. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients. Thromb Haemost. 1997;78(4): 1167-1172.
24.
Athyros VG, Kakafika AI, Karagiannis A., Mikhailidis DPDo we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis. 2008;200(1):1-12.
